Programme - MelNet€¦ · 7 Programme Welcome Room: The Great Room 0830 Welcome 0845 Opening...

8

Programme2-3 November 2018

Cordis Hotel, Auckland

Proudly hosted by

PartnersGold Partners

Silver Partners

Bronze Partners

Scholarship Partners

3

ContentsBreakout session locations 5

Programme 7

Keynote speakers 17

General information 30

4

WelcomeIt is our pleasure to extend a very warm welcome to you at the fifth New Zealand Melanoma Summit.

New Zealand melanoma incidence and death rates are among the highest in the world. Your participation at the Summit reflects the seriousness of melanoma as a public health issue in our country and shows willingness to collaborate to address these alarming trends. We thank you for making the time to be part of this important two-day event.

In planning the programme, our Committee has endeavoured to include a wide range of professionals across the field of melanoma. The faculty for this years’ Summit includes international and New Zealand speakers who are recognised as world leaders across the spectrum of melanoma care. We have also strived to ensure a balance between presentation and participation so you can contribute and gain as much from the two days as possible.

We look forward to outcomes from the Summit that will make a positive difference to reducing the incidence and impact of melanoma in New Zealand.

Mr Gary Duncan

MelNet Executive Committee Co-Chair

Dr Chris Boberg

MelNet Executive Committee Co-Chair

Join MelNet today!MelNet is looking for members, and membership is free!

By becoming a member you can add your voice to the growing number of health professionals concerned about reducing the incidence and impact of all skin cancers, including melanoma.

Other benefits:• Receive updates on upcoming courses, events and news

• Post your research and activities on the MelNet portal

• Receive regular e-newsletters with upcoming activities and recent publications, and opportunities for member feedback and advocacy

• Have access to contact details for fellow professionals through the directory of members.

www.melnet.org.nz

5

Breakout session locations

1. Skin Cancer Symposiums Ltd and New Zealand Skin Cancer Doctors

2. Bernier Pharmaceuticals

3. Roche Products (NZ) Limited

4. Johnson & Johnson Pacific

5. Skin Cancer College Australasia

6. Esteem Healthcare

7. Cancer Society of New Zealand Incorporated

8. Australia and New Zealand Melanoma Trials Group

9. La Roche-Posay

10. Edgewell Personal Care

● Registration Desk and Medical Books NZ (from 12PM Friday)

Pre-function Area – Trade display locations

The Great Room

Rest Room

Crystal Room

Rest Room

GalleryRoom

4GalleryRoom

3

Hotel Entrance

III

II

I

The Great RoomPre-function Area

The Great Room

Pre-function Area

FIR

E E

XIT

FIR

E E

XIT

FIR

E E

XIT

FIR

E E

XIT

FIR

E E

XIT

MA

IN E

NTR

AN

CE

TOIL

ETS

FIR

E E

XIT

FIR

E E

XIT

FIR

E E

XIT

FIR

E E

XIT

REG

OR

EGO

12

10

9

8

7

6

5

43

II

I

6

PROTECTION REQUIRED

Wear a hat and sunglasses

Data provided by NIWA

SUN PROTECTION ALERT

10 AM:50 3 PM

:30

uv2Dayuv2Day App provides forecasts of the UV Index throughout the day at your nearest selectable location, within New Zealand, Australia and the South Pacific (incl. Antarctica).

The app is useful for activity planning and for public education on the UVI.

Three recommended ways for New Zealanders to check daily

UV danger

sunsmart.org.nz

Sun Protection AlertFrom September to April (the daylight saving months), the Sun Protection Alert gives the UV danger period for a number of New Zealand cities and towns. It is available on the MetService website and App and in the weather section of the main newspapers.

The key message on the example below is that you need to protect your skin and eyes from 10.50am to 3.30pm.

It also reminds you about some of the SunSmart steps to use – in this example, wear a hat and sunglasses.

NIWA UV forecasts NIWA website displays UVI forecasts for specific sites within New Zealand, Australia and the South Pacific (incl. Antarctica).

7

Programme

Welcome

Room: The Great Room

0830 Welcome

0845 Opening address

Mr Andrew Connolly, Chair, Medical Council of New Zealand

0855 2018 New Zealand Melanoma Summit overview

Dr Chris Boberg, Chair, 2018 New Zealand Melanoma Summit Planning Committee and Co-Chair, MelNet

0905 A challenge to participants from a patient perspective

Leisa Renwick

Session 1: Epidemiology and primary prevention

Chair: Tane Cassidy, General Manager Communications and Capacity, Health Promotion Agency


0910 Global trends in melanoma incidence and mortality and emerging issues in primary prevention and risk assessment

Professor David Whiteman, Senior Scientist and Deputy Director, QIMR Berghofer Medical Research Institute, Queensland, Australia

0940 Trends in melanoma incidence and mortality, and risk assessment in New Zealand

Dr Mary Jane Sneyd, Senior Research Fellow and Deputy Director, Hugh Adam Cancer Epidemiology Unit, Dunedin School of Medicine, University of Otago

Kindly sponsored by the Health Promotion Agency

0955 Questions and discussion

1015 Morning tea Pre-function Area

Session 2: Clinical diagnosis

Chair: Dr Chris Boberg, Co-Chair, MelNet Room: The Great Room

1045 Artificial intelligence and advances in dermatoscopy and teledermatoscopy

Associate Professor Cliff Rosendahl, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

Friday 2 November

8

1115 Nodular melanoma (an important issue for New Zealand)

Professor John Kelly, Consultant Dermatologist, Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia

1145 Diagnosis and changes in histological classification: 8th edition American Joint Committee on Cancer

Dr Michael Hitchcock, Dermatopathologist, Auckland Anatomic Pathology Services, Auckland District Health Board


1230 Lunch Pre-function Area

Session 3: Melanoma management

Chair: Mr Gary Duncan, Co-Chair, MelNet Room: The Great Room

1315 The critical role of sentinel node biopsy in the management of melanoma

Professor John Thompson, Melanoma Institute Australia and Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia

1345 Melanoma Standards update

Dr Richard Martin, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board

1400 Questions and discussions

1415 Session 4: Concurrent breakout session 1

[4A] MelNet melanoma multi-disciplinary meeting: challenging cases 1

Chair: Dr Richard Harman, Clinical Director, Department of General Surgery and Endocrine, Breast and Melanoma Surgeon, North Shore Hospital

Room: Crystal 1

In this session, a multi-disciplinary panel will discuss the clinical management of a range of challenging or unusual cases of melanoma. A similar session will be repeated in Breakout Session 5A with a different panel and cases.

Delegates are encouraged to attend only one of these sessions.

Panel:

• Dr Mike McCrystal, Medical Oncologist, Auckland

• Dr Gareth Rivalland, Medical Oncologist, Auckland

• Professor John Thompson, Melanoma Institute Australia and Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia

• Mr Chris Adams, Plastic and Reconstructive Surgeon, Hutt Valley District Health Board

• Dr Maria Pearse, Radiation Oncologist, Auckland Hospital

• Dr Fiona Larsen, Dermatologist, Fiona Larsen Dermatology, Auckland

• Dr Franz Strydom, GP with special interest in skin cancer, Skinspots Skin Cancer Clinic, Mt Maunganui

9

[4B] Dermatoscopy in action

Chair: Dr Chris Boberg, Co-Chair, MelNet Room: Gallery 4

This session presented by Associate Professor Cliff Rosendahl will teach the basics of the ‘chaos and clues’ approach to dermatoscopy in diagnosing melanoma and will demonstrate its practical application to specific cases.

Presenter:

• Associate Professor Cliff Rosendahl, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

[4C] Sunscreens: Current issues and controversies

Chair: Megan Chapman, Manager Child and Family Health, Health Promotion Agency Room: Crystal 2

In this session Professor David Whiteman will provide an overview of molecular studies of sunscreen in humans. Belinda Castles (Senior Writer, Consumer NZ) will then discuss consumer concerns about sunscreen, including New Zealand’s lack of regulations and the results of Consumer NZ’s testing programme. This will be followed by a discussion on the implications of this information for New Zealanders.

Presenters:

• Professor David Whiteman, Senior Scientist and Deputy Director, QIMR Berghofer Medical Research Institute, Queensland, Australia

• Belinda Castles, Senior Writer, Consumer NZ

[4D] Melanoma Research and Therapy Special Interest Group: Translational and collaborative melanoma research in New Zealand

Co-chairs: Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services and Professor Mike Eccles, Professor, Department of Pathology, University of Otago

Room: Gallery 3

This session will discuss three translational and collaborative research projects relating to melanoma, and the implications this research may have on the way melanoma is managed and treated in future.

Presenters:

• Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology ServicesA Randomised Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma

• Professor Peter Shepherd, Deputy Director Maurice Wilkins CentreCombination therapy for melanoma

• Professor Mike Eccles, Professor, Department of Pathology, University of OtagoEpigenomic profiling to predict patient response to melanoma immunotherapy

1515 Afternoon tea Pre-function Area

10


[5A] MelNet melanoma multi-disciplinary meeting: challenging cases 2

Chair: Dr Richard Harman, Clinical Director, Department of General Surgery and Endocrine, Breast and Melanoma Surgeon, North Shore Hospital

Room: Gallery 4

This session will focus on the clinical management of challenging or unusual cases of melanoma. A multi-disciplinary panel will discuss a range of cases. This will be a repeat of Breakout Session 4A but with a different panel and cases.

Delegates are encouraged to attend only one of these sessions.

Panel:

• Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services

• Dr Susan Seifried, General Surgeon, Nelson Marlborough District Health Board

• Mr Jeremy Simcock, Plastic Surgeon, Canterbury District Health Board

• Dr Fergus Oliver, Dermatologist, Dermatopathologist and Mohs Surgeon, Auckland Skin and Cancer Foundation

• Dr Mark Foley, Skin Cancer Doctor, The Skin Clinic Marlborough

[5B] Difficult cases at the clinical pathology interface

Chair: Dr Ben Tallon, Dermatologist SKIN Dermatology Institute Tauranga Room: Crystal 2

This panel session will explore the interface between histological and clinical diagnosis using a range of difficult cases such as dysplastic naevi, spitz tumours, and BAPomas as examples.

Panel:

• Professor John Kelly, Consultant Dermatologist, Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia

• Associate Professor Cliff Rosendahl, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

• Dr Michael Hitchcock, Dermatopathologist, Auckland Anatomic Pathology Services, Auckland District Health Board

• Dr Richard Massey, Pathologist, Pathlab Bay of Plenty

[5C] Use of technologies and their potential role in prevention and diagnosis

Chair: Adrian Bowling, Chief Technology Officer, Molemap New Zealand Room: Crystal 1

This session will discuss the current impact of technology and its role in the future of prevention and early detection of melanoma.

Panel:

• Dr Martin Haskett, Consultant, MoleMap Australia

• Maria Buckingham, Group Training and Quality Manager, MoleMap Australia

• Ming Cheuk, Chief Technology Officer, Spark64

• Hayden Laird, Chief Executive, FirstCheck

• Michel Nieuwoudt, Senior Research Fellow, School of Chemical Sciences and Photon Factory, University of Auckland

11

[5D] Snapshots of clinical innovations

Chair: Dr Chris Boberg, Co-Chair, MelNet Room: Gallery 3

Presenters whose submitted abstracts have been selected will provide snapshots clinical innovations.

Presenters:

• Dr Richard Martin, Surgical Oncologist New Zealand Melanoma Unit, Waitemata District Health Board

The use of sentinel node biopsy and novel molecular approaches to improve triage in high risk cutaneous SCC of the head and neck

• Michael Sunderland, Intern, Waitemata District Health Board

Teledermatology and e-referral grading for melanoma, a successful model of care

• Dr Rebecca Teague, Surgical Registrar, Waitemata District Health Board

The virtual skin lesion clinic (VLC) – an evaluation of a new triage system for melanoma

• Dr Keith Monnington, President, Skin Cancer College Australasia and GP with special interest in skin cancer, Skinspots Skin Cancer Clinic, Mount Maunganui

Learning every day

• Daniel Wen, Medical Student, University of Auckland

Waitemata District Health Board Skin Service: GP surgeon scheme, an effective model of care

1645 Session 6: Day one breakout sessions – highlights and recommendations


1715 MelNet AGM Crystal II

12

1745 Poster presentation and cash bar Room: Pre-function Area

Presenters

• Heather Knewstubb, Health Promotion Advisor, Cancer Society of New Zealand National OfficeProtecting our tamariki from UV Radiation

• Dr Rebecca Bell, Researcher, Health Promotion Agency Barbara Hegan, Senior Advisor Skin Cancer Prevention, Health Promotion AgencyCommunicating UVR risk to New Zealanders: exploring key knowledge gaps

• Ryan Gage, Assistant Research Fellow, University of Otago, WellingtonRecent sun safety observations in Aotearoa New Zealand: Implications for policy and research

• Ryan Gage, Assistant Research Fellow, University of Otago, WellingtonStrategies to strengthen skin cancer prevention in New Zealand: Views of key stakeholders

• Bronwen McNoe, Research Fellow Cancer Society Social and Behavioural Research Unit, Department of Preventive and Social Medicine, University of OtagoSunbeds and the second-hand market in New Zealand

• Narelle Williams, Senior Project Officer, Australia and New Zealand Melanoma Trials GroupExercise behaviours and fatigue in patients receiving immunotherapy for advanced melanoma: a cross-sectional survey

• Ruth Nicholson, Owner and Course Director, NZ Laser Training LtdUnderstanding Laser and IPL and the risk of accidental removal of malignancies – an industry update

• Dr Franz Strydom, GP with special interest in skin cancer, Skinspots Skin Cancer Clinic, Mt MaunganuiABCD versus SCAN

• Valeriya Nazarova, Department of Biotherapy, N.N Blokhin Russian Cancer Research Centre, MoscowGenetic analysis of ocular melanoma

• Sandra Fitzgerald, PhD student, University of Auckland Development of plasma genomic biomarkers for mutation detection and monitoring in New Zealand cancer patients

1845 Conference dinner

Guest speaker Room: The Great Room

Responsible hostingThe MelNet Executive Committee and the Health Promotion Agency are responsible hosts. Therefore food, water and non-alcoholic drinks will be offered at the poster session and conference dinner.

13

Saturday 3 November0715 Session 7: Immunotherapy – the New Zealand story: a breakfast panel discussion

Co-Chairs: Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services and Mr Gary Duncan, Co-Chair, MelNet


To commence with a buffet breakfast, this session will analyse the impact of immunotherapies on melanoma treatment in New Zealand over the past two years. This will be supported by stories told by survivors of their experiences.

Presenters:

• Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services

• Leisa Renwick, Patient advocate

• Shane Callaghan, Patient

Proudly supported by MSD NZ LTD

Session 8: Advances in therapy and care

Chair: Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services


0830 Standard of care for stage IV metastatic melanoma and future prospects

Associate Professor Victoria Atkinson, Senior Staff Specialist Medical Oncologist, Princess Alexandra Hospital, Brisbane, Australia

0900 The nurse’s role in supporting patients receiving immunotherapy

Dr Donna Milne, Melanoma Nurse Consultant and Clinical Nurse Researcher, Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria, Australia


Session 9: Advances in melanoma research in New Zealand

Chair: Professor Mike Eccles, Professor, Department of Pathology, University of Otago Room: The Great Room

0945 New opportunities for personalised immunotherapy

Professor Rod Dunbar, Director, Maurice Wilkins Centre Auckland

0955 New combinations of drugs to treat melanoma

Professor Peter Shepherd, Deputy Director, Maurice Wilkins Centre Auckland

1005 Biomarkers of response to immune checkpoint inhibitors used to treat melanoma

Professor Mike Eccles, Professor, Department of Pathology, University of Otago

1015 Stage III melanoma – not as easy as it looks

Dr Richard North, Medical Oncologist, Bay of Plenty Cancer Centre

1025 Testing, testing….trials here and on the horizonDr Sanjeev Deva, Medical Director, Auckland Cancer Trials Centre and Medical Oncologist

14

1035 Morning tea Pre-function Area


[10A] GPs with a special interest in skin cancer

Chair: Dr Chris Boberg, President, New Zealand Skin Cancer Doctors Room: Crystal 1

Intended for those who are part of or interested in joining New Zealand Skin Cancer Doctors. The session will provide an overview of New Zealand Skin Cancer Doctors and the work they do. It will also include a discussion of interesting dermatoscopic and surgical cases. Attendees are encouraged to bring along cases to discuss.

[10B] NZ Skin Cancer Primary Prevention and Early Detection Strategy 2017 to 2022: health check on progress

Chair: Megan Chapman, Manager Child and Family Health, Health Promotion Agency Room: Gallery 3

Intended for those working in primary prevention, this session will review primary prevention and early detection long term outcomes identified in the New Zealand Skin Cancer Primary Prevention and Early Detection Strategy 2017 to 2022. The session will conclude with a discussion on the ‘When to apply sunscreen’ – draft Position Statement resulting from the 2018 Brisbane Sunscreen Summit (as discussed in breakout 4C) and its potential incorporation into the Strategy.

[10C] The essential role of the nurse in melanoma care

Chair: Trish Leathem, Skin Cancer Clinical Nurse Specialist, Middlemore Hospital, Counties Manukau District Health Board

Room: Crystal 2

Intended for nurses. This session will commence with a presentation from Dr Donna Milne, who through detailed case studies will address the essential role of nurse practitioners in the care of patients with melanoma. During the second half of the session, Katy Doherty (Dermatoscopy Nurse and Skin Cancer Detection Care, Torbay Skin) will discuss the role of nurses in the early detection of skin cancer through dermatoscopy. There will be time for questions and discussion after each presentation.

Presenter:

• Dr Donna Milne, Melanoma Nurse Consultant and Clinical Nurse Researcher, Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria, Australia

• Katy Doherty, Dermatoscopy Nurse and Skin Cancer Detection Care, Torbay Skin, Auckland

15

[10D] Research innovations

Chair: Mr Jeremy Simcock, Plastic Surgeon, Canterbury District Health Board Room: Gallery 4

Presenters whose submitted abstracts have been selected will provide snapshots of innovative research projects.

Presenters:

• Elizabeth Paton, Chief Executive Officer, Australia and New Zealand Melanoma Trials GroupA randomised trial of excision margins for melanoma (ANZMTG 03.12 MelMarT)

• Dr Ian Ong, Surgical Registrar, North Shore HospitalQuality assurance measures in axillary clearance for metastatic cutaneous melanoma

• Tess Ostapowicz, Research Nurse Malaghan Institute, Capital Coast District Health BoardThe Melvac Study –a shared journey

• Dr Catherine Barrow, Medical Oncologist, Wellington Blood and Cancer CentreImpact of checkpoint blockade immunotherapy (Pembrolizumab or Nivolumab) on vaccine-induced T cell responses

• Narelle Williams, Senior Project Officer, Australia and New Zealand Melanoma Trials GroupAustralasian Merkel Cell Carcinoma Interest Group (AMIGOs) – improving the outlook for patients with Merkel cell carcinoma

• Sandra Fitzgerald, PhD student, University of AucklandDevelopment of plasma genomic biomarkers for mutation detection and monitoring in New Zealand cancer patients

1200 Session 11: Day two breakout sessions – highlights and recommendations


1215 Session 12: Managing stage III melanoma in the era of immune and targeted therapy

Chair: Dr Richard Martin, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board


Professor John Thompson, Melanoma Institute Australia and Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia

The role of the surgical oncologist in managing advanced stage III melanoma in the era of immune and targeted therapy

Associate Professor Victoria Atkinson, Senior Staff Specialist Medical Oncologist, Princess Alexandra Hospital, Brisbane, Australia

Neoadjuvant and adjuvant management of stage III melanoma – best practice in 2018

1250 Lunch Pre-function Area

16

Session 13: Looking to the future of melanoma – moving the goalposts

Co-chairs: Trish Leathem, Skin Cancer Clinical Nurse Specialist, Middlemore Hospital, Counties Manukau District Health Board and Mr Gary Duncan, Co-Chair, MelNet


1330 New Zealand’s quest for excellence in the delivery of melanoma careDr Chris Jackson, Medical Director, Cancer Society of New Zealand

1340 Panel: The future of melanoma prevention, diagnosis, treatment, care and researchAssociate Professor Cliff Rosendahl, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

Associate Professor Victoria Atkinson, Senior Staff Medical Oncologist, Princess Alexandra Hospital Brisbane, Australia

Dr Chris Jackson, Medical Director, Cancer Society of New Zealand

Dr Donna Milne, Melanoma Nurse Consultant and Clinical Nurse Researcher, Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria, Australia

Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services

Leisa Renwick, Patient advocate

Professor David Whiteman, Senior Scientist and Deputy Director, QIMR Berghofer Medical Research Institute, Queensland, Australia

Professor John Thompson, Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia

1415 Wrap up and recommendations

Mr Gary Duncan, Co-Chair, MelNet

1445 Closing remarksMr Gary Duncan and Dr Chris Boberg, Co-Chairs, MelNet

1500 Close

1515 Melanoma Research and Therapy Special Interest Group: Cancer Hub Platform

Chair: Professor Mike Eccles, Professor, Department of Pathology, University of Otago Room: Crystal II

The Melanoma Research and Therapy Special Interest Group is a national and inclusive multi-disciplinary group of melanoma health professionals and researchers seeking to achieve consensus on current issues, implement solutions to these issues and improve upon current standards of care by promoting and facilitating research in melanoma.

Following the conclusion of the 2018 New Zealand Melanoma Summit, a one-hour meeting of the Melanoma Research and Therapy Special Interest Group will be held to discuss the development of a Cancer Hub Platform. The purpose of this platform is to store and share research data and next generation sequencing data produced from the tissue of cancer patients, facilitating greater networking and collaboration between cancer researchers in New Zealand.

All health professionals and researchers with a special interest in melanoma research and therapy are invited to this MelNet-sponsored meeting.

17

Keynote speakers

Professor John ThompsonAO, MD, FRACS, FACS

Melanoma Institute Australia and Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia

Date: Friday 2 November | Time: 1315

Address: The critical role of sentinel node biopsy in the management of melanoma

Date: Saturday 3 November | Time: 1215

Address: Managing stage III melanoma in the era of immune and targeted therapy

Professor Thompson is internationally recognised for his leadership in developing the sentinel node biopsy technique in the management of melanoma. He pioneered the Isolated Limb Perfusion and has trained surgeons around the world in the technique which is now performed regularly. Professor Thompson was the Director of Sydney Melanoma Unit from 1998 and thereafter Executive Director of Melanoma Institute Australia until the end of 2016. He is a past President of the International Sentinel Node Society, and was Chairman of the Australian and New Zealand Melanoma Trials Group for 15 years. He is a member of the Melanoma Staging Committee of the American Joint Committee on Cancer, and chair of the Working Group responsible for updating the Clinical Practice Guidelines for the Management of Cutaneous Melanoma in Australia and New Zealand. He is an Honorary Fellow of the American Surgical Association and the American College of Surgeons, and an Inaugural Fellow of the Australian Academy of Health and Medical Sciences. Professor Thompson is author of over 700 peer-reviewed scientific articles and holds positions on the editorial boards of several international journals. Professor Thompson has received several awards for his contribution to cancer research and medical education.

Professor David WhitemanBMedSc, MBBS(Hons), PhD, FAFPHM

Senior Scientist and Deputy Director, QIMR Berghofer Medical Research Institute, Queensland, Australia


Address: Global trends in melanoma incidence and mortality and emerging issues in primary prevention and risk assessment

Professor David Whiteman is a medical epidemiologist with a special interest in the causes, control and prevention of cancer. He has an international reputation for research into melanoma and skin cancer, particularly discovering how environmental and genetic factors interact to cause cancer, and then applying this knowledge to the prevention and control of disease. Professor Whiteman is responsible for the QSkin study, the world’s largest prospective study of skin cancer with almost 44,000 participants. As part of this study, Professor Whiteman led the development of a risk prediction model to help people aged 40 and over predict their risk of developing melanoma over the next three and a half years. Research into the safety and use of sunscreen is also part of Professor Whiteman’s portfolio. In March this year Professor Whiteman convened a Sunscreen Summit in Brisbane to identify strategies to educate Australians about sunscreen’s role in sun protection and find new ways to improve public understanding of how to prevent skin cancer. In addition to his research activities, he is a Fellow of the Australian Academy of Health and Medical Sciences, a Fellow of the Australasian Faculty of Public Health Medicine, a member of the Academy of the National Health and Medical Research Council of Australia (NHMRC) and currently Chairs the Barrett’s Neoplasia Guidelines Committee for the Cancer Council Australia and the Breast Cancer Risk Factors Working Group for Cancer Australia.

19

Associate Professor Cliff RosendahlMBBS PhD

Course Coordinator of the Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia


Address: Artificial intelligence and advances in dermatoscopy and teledermatoscopy

Associate Professor Cliff Rosendahl is a medical practitioner with over 40 years’ experience. He has a background in general practice and forensic medicine, and has worked in a Brisbane suburban practice as a general practitioner with a special interest in skin cancer, particularly melanoma. Associate Professor Rosendahl has collaborated with colleagues in Brisbane and Austria to research the early diagnosis of melanoma, and together they have evaluated and promoted the diagnostic methods ‘Chaos and Clues and Prediction without Pigment’. He is founder and a coordinator of the Skin Cancer Audit and Research Database (SCARD). He has published over 50 papers in peer-review scientific journals, is co-author of the textbook Dermatoscopy which is published in eight languages, and is a contributing author to several other textbooks in English and two in Spanish.

Professor John KellyAM.MBBS, MD, FACD

Consultant Dermatologist, Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia


Address: Nodular melanoma (an important issue for New Zealand)

Professor John Kelly founded one of Australia’s largest multi-disciplinary treatment services for melanoma, the Victorian Melanoma Service, at the Alfred hospital in 1994. He trained as a dermatologist in Melbourne and undertook his Doctorate at the Melanoma Clinic, University of California, San Francisco, on the subject of melanoma diagnosis and management. With a longstanding interest in melanoma research, Professor Kelly has published more than 100 papers, particularly with respect to clinical features, diagnosis and treatment. Professor Kelly has served on the board of the Australia and New Zealand Melanoma Trials Group, and is a member of the Executive Steering Committee and contributing author for the wiki-based Australian Clinical Practice Guidelines for the Diagnosis and Management of Melanoma 2017.

20

Associate Professor Victoria AtkinsonMBBS, FRACP

Senior Staff Specialist Medical Oncologist, Princess Alexandra Hospital, Brisbane, Australia


Address: Standard of care for Stage IV metastatic melanoma and future prospects


Address: Managing stage III melanoma in the era of immune and targeted therapy

Associate Professor Victoria Atkinson is a medical oncologist who practises as a Senior Staff Specialist at the Princess Alexandra Hospital in Brisbane, Australia. She also practises private practice at Greenslopes Private Hospital and is affiliated with the University of Queensland Clinical School of Medicine where she was appointed as an Associate Professor in 2016. Associate Professor Atkinson graduated from the University of Queensland in 1998. She then completed her physician training at the Royal Brisbane and Women’s Hospital before training in medical oncology at the Princess Alexandra and Royal Brisbane Hospitals, completing her fellowship in 2006. Her main tumour interests are melanoma oncology. She has extensive experience with targeted therapies for melanoma including Vemurafenib, Dabrafenib, Trametinib, Ipilimumab and Nivolumab and is involved as Principal Investigator or Co-Investigator in clinical trials at both Princess Alexandra Hospital and Greenslopes Private Hospital.

Dr Donna MilneBNurs, Dip CanNurs/Pall, MNurs, PhD

Melanoma Nurse Consultant and Clinical Nurse Researcher, Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria, Australia


Address: The nurse’s role in supporting patients receiving immunotherapy

Dr Milne is a registered nurse who has been working in cancer care for 22 years. Her PhD investigated the perceptions of palliative care services held by people with advanced cancer. Her current research activities focus on identifying the needs of patients with melanoma and their family members, and the experiences and expectations of patients being treated with immunotherapies. Dr Milne is on the Executive of the Australia and New Zealand Melanoma Trials Group, and is an active member of the Cancer Nurses Society of Australia, Psycho-Oncology Co-operative Research Group and the International Society of Nurses in Cancer Care. Dr Milne sits on national and international nursing advisory boards that advise on the educational and support requirements of patients with melanoma. She has published numerous papers in peer-reviewed journals.

21

Leisa RenwickPatient advocate


Address: Challenge to delegates from a patient perspective


Address: Immunotherapy - the New Zealand story: a breakfast panel discussion

Leisa Renwick is a maths teacher at Mount Maunganui College, Tauranga. She is a mother of three and married to husband Wayne. In May 2015, Leisa was diagnosed with stage four melanoma and given weeks to live. Leisa was treated with dabrafenib, which she received under a compassionate programme. She then self-funded Keytruda and is now in remission. Since her diagnosis, Leisa was part of a strong campaign for Keytruda be made available to all New Zealander’s with advanced melanoma. In March 2016, she was one of a group of patients who presented a petition of more than 11,000 signatures to Parliament requesting extra funding for Pharmac so Keytruda could become more accessible to New Zealanders. Following this petition, the Government announced a $39 million funding boost for Pharmac and Pharmac made Keytruda publicly available from September 2016. Leisa was named the Herald’s New Zealander of the Year in December 2016 and has spoken about her journey at many public events.

Mr Andrew ConnollyMB ChB, FRACS

Chairperson, Medical Council of New Zealand


Opening address

Mr Connolly is a general and colorectal surgeon. He is employed full time at Counties Manukau District Health Board where he has been the Head of Department of General and Vascular Surgery since 2003. He has a strong interest in surgical education and training, and acute surgical care, as well as taking an active role with surgical research into enhanced recovery. Appointed to the Medical Council of New Zealand in November 2009 and held the position of chair since 2014, Mr Connolly has a strong interest in governance and clinical leadership. He has served on numerous national advisory groups and committees, including the 2015 Review of Capability and Capacity in the Health System. He has previously held the role of Presiding Member of the Lotteries Health Research Distribution Committee, chaired a Ministerial review of the impact of the elective waiting times policy and was a member of the review panel of the New Zealand Cancer Registry. He is currently on the Southern Partnership Group overseeing planning for the rebuild of the Dunedin Hospital.

22

40 Rocklands Road, North Sydney NSW 2060 I P: +61 2 9911 7329 I F: +61 2 9954 9435 I E: [email protected] I W: www.anzmtg.org

The Australia and New Zealand Melanoma Trials Group is the national cancer collaborative research group developing quality investigator-initiated clinical trials addressing unmet clinical questions in melanoma and skin cancers. We are the only dedicated melanoma and skin cancer collaborative cancer clinical trials group in Australia and New Zealand, working together with our international membership network to improve the lives of patients and families affected by these cancers.

We facilitate, design, develop, conduct, analyse, publish and promote innovative research, particularly clinical trials, led by expert melanoma and non-melanoma skin cancer researchers across all aspects of patient care from prevention, diagnosis through to intervention research for later stage diagnoses.

Our aim is to accelerate research progress by connecting and supporting clinicians and researchers to develop new concepts, secure funding, undertake research and broadly disseminate the results to guide and improve patient care and treatment.

ANZMTG has an active membership which now includes 1,350+ members in 31 countries worldwide, representing all relevant clinical and research disciplines, allied and public health, nursing and research professionals, statisticians, health economists, scientists, policy-makers, patients, family members and other valued stakeholder representatives (i.e. advocacy groups, government + industry).

With thanks to our dedicated members we have a proven track record of successful trial completion and an impressive portfolio of innovative research underway (25+ phase Ib-IV trials, with many new trials in the pipeline). We are thankful for the support of our robust growing network of 80+ hospitals and clinics (throughout 15 countries). We acknowledge our researchers who have secured grant funding in excess of $AUD16million; 100% of which goes to support our research.

New research ideas and new members always welcome (PS. It’s free to join!) For more information please contact one of our friendly team [email protected]

What is AMIGOs? Coordinated by the ANZMTG, the Australasian Merkel Cell Carcinoma Interest Group (AMIGOs) is a network supporting experts interested in Merkel Cell Carcinoma (MCC) diagnosis, research and treatment. AMIGOs is committed to supporting research and the co-ordination of patient care that leads to improved quality of life for patients with MCC. For updates, sign up as an AMIGOs member by contacting [email protected]

What is AOMA? Coordinated by the ANZMTG, the Australasian Ocular Melanoma Alliance (AOMA) is a recently established network of clinicians, scientists and patient advocates collaborating together to create new and innovative research to help patients with ocular melanoma. For updates, sign up as an AOMA member by contacting [email protected]

23

Dr Mary Jane SneydBSc MB CHB PhD

Senior Research Fellow and Deputy Director, Hugh Adam Cancer Epidemiology Unit, Dunedin School of Medicine, University of Otago


Address: Trends in melanoma incidence and mortality, and risk assessment in New Zealand

Dr Sneyd is a cancer epidemiologist whose main research interests include descriptive, analytical, and survival studies of melanoma, myeloma, and colorectal, breast and prostate cancers. As well as many descriptive epidemiological projects, she has carried out several national case-control studies of cancer in New Zealand and has developed New Zealand– specific risk predictor models for melanoma and breast cancer for use in primary care.

Dr Michael HitchcockMBChB

Dermatopathologist, Anatomic Pathology Services, Auckland District Health Board


Address: Diagnosis and changes in histological classification: 8th edition American Joint Committee on Cancer

Dr Michael Hitchcock is a pathologist at Anatomic Pathology Services, Auckland District Health Board, specialising in dermatopathology. After gaining his FRCPA in Auckland in 1989, Dr Hitchcock completed American Boards in anatomic pathology and dermatopathology at Duke University Medical Center in North Carolina. Since then he has worked at Duke, Wake Forest University and in private practice. He has been active at all levels of the American Society of Dermatopathology, taught dermatopathology fellows at Wake, and dermatology residents at East Carolina University.

Dr Richard MartinMBChB, FRACS, ChM

Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board


Address: Melanoma Standards update

Dr Martin is a melanoma surgical oncologist, managing over 500 melanoma cases each year. A New Zealand trained general surgeon, he spent two and a half years at the Sydney Cancer Centre specialising in melanoma and head/neck surgery. Most of his time was spent at the Sydney Melanoma Unit, the largest treatment and research facility for melanoma in the world. Dr Martin chairs the National Melanoma Standards group for the Ministry of Health plus the Auckland Regional Melanoma Multidisciplinary meeting and sits on the executive committees of MelNet, Australia and New Zealand Melanoma Trials Group and Melanoma New Zealand. He has published in numerous academic journals, is a regular presenter at national and international conferences and is actively involved in research and clinical trials.

24

Dr Rosalie StephensMBChB, FRACP, MD

Medical oncologist, Auckland District Health Board Oncology Services


Address: Immunotherapy - the New Zealand story: a breakfast panel discussion

Dr Stephens is a medical oncologist at Auckland Hospital, specialising in the treatment of patients with melanoma, breast and gynaecological cancers. Dr Stephens completed a fellowship at the Royal Marsden Hospital in London between 2010 and 2013 where she undertook clinical and translational research in melanoma, kidney, breast and gynaecological cancers. In 2015, Dr Stephens completed her post-graduate research in tumour biology and evolution attaining a Doctor of Medicine degree from the University of London. Melanoma is an active research focus, aiming to improve patient outcomes by access to new, improved therapies. Dr Stephens is a Trustee on the board of Melanoma New Zealand, a member of the New Zealand Gynaecological Cancer Group and a founder of the Melanoma Research and Therapy Special Interest Group. She has published numerous papers in peer-reviewed journals and contributed to patient and public education.

Professor Rod DunbarMBChB, PhD

Director Maurice Wilkins Centre


Address: New opportunities for personalised immunotherapy

Professor Dunbar holds both a medical degree (MBChB) and a PhD from the University of Otago. He spent six years as a post-doctoral research fellow in human immunology at the University of Oxford, before returning to New Zealand in 2002 under a Wellcome Trust International Senior Research Fellowship. In 2009 he was appointed the Director of the Maurice Wilkins Centre, a national Centre of Research Excellence that promotes a multi-disciplinary approach to the discovery of new medicines and vaccines. His main research area is human cellular immunology, especially the development of therapies for cancer that utilise the immune system. He cloned the first T cells recognising the cancer antigen NY-ESO-1, leading to the development of a transgenic T cell receptor that has shown promising results in early phase clinical trials in melanoma and sarcoma. In 2017 he and Professor Margaret Brimble founded SapVax LLC, a US-based company developing novel vaccines for use in immune therapy of melanoma and other cancers.

25

Professor Peter ShepherdPHD

Deputy Director Maurice Wilkins Centre


Address: New combinations of drugs to treat melanoma

Professor Peter Shepherd graduated from Massey University and, following postdoctoral positions at Harvard and Cambridge became a staff member at University College London where he was promoted to Professor in 2003. There he became involved in biotechnology and was named London Young Biotechnology Entrepreneur of the year in 2002. Since moving back to Auckland in 2004 he has continued to focus on research of the signal transduction pathways in the cell and how defects in these lead to the development of cancer and diabetes. He founded biotechnology company Symansis to develop novel tools for drug discovery and was co-founder of drug development company Pathway Therapeutics. Professor Shepherd has published in many peer-reviewed journals and is Chair of Queenstown Molecular Biology Meetings Society.

Professor Mike EcclesBSc(Hons), PhD

Professor, Department of Pathology, University of Otago


Address: Biomarkers of response to immune checkpoint inhibitors used to treat melanoma

Professor Eccles specialises in molecular cancer research, with expertise in cancer genetics, human molecular genetics, and developmental genetics. His research background involves gene and chromosome mapping, epigenetic studies of gene regulation, and impacts on cell behaviour of gene expression. A current research focus is identifying genomic and epigenomic features characterising metastatic versus primary melanomas. Since 2006 Professor Eccles has been the Chair in Cancer Pathology of the New Zealand Institute for Cancer Research Trust. He has published numerous papers in peer- reviewed journals and is currently heading a research group in the Developmental Genetics and Pathology Laboratory in the Department of Pathology at the University of Otago. Professor Eccles is a Director of the New Zealand Institute for Rare Disease Research Ltd, a Principal Investigator (non-management) in the Maurice Wilkins Centre for Molecular Biodiscovery, a founding member of MelNet and a founding member of Polycystic Kidney Disease Australia.

26*by number vs. Banana Boat Sport Very High Protection Sunscreen Lotion SPF 50+ *by number vs. Banana Boat Kids Very High Protection Sunscreen Lotion SPF 50+

FUN IN THE SUN. SIMPLIFIED.

27

Dr Richard NorthBHB, MBChB, FRACP

Medical Oncologist, Bay of Plenty Cancer Centre


Address: Stage III melanoma – not as easy as it looks

Dr Richard North is a medical oncologist with a specific interest in melanoma, gastro-intestinal and lung cancers. Based at the Bay of Plenty Cancer Centre in Tauranga and Whakatane, Dr North trained in Auckland and Waikato before moving to Newcastle, Australia to complete his fellowship training. Dr North is and has been the principal investigator in many phase III multinational trials in oncology since moving to Tauranga in 2008. As the first medical oncologist based in Tauranga and Whakatane, he has also been instrumental in building and expanding the service in the region. Dr North has been a member of Cancer Control New Zealand and is currently the chair of the Ministry of Health Medical Oncology Work Group, a committee dedicated to improving medical oncology services throughout the country. Dr North has an academic position with the University of Auckland School of Medicine to teach 4th year and final year medical students based in the Bay of Plenty. He is also an examiner for the Royal Australasian College of Physicians.

Dr Sanjeev DevaMBChB, FRACP

Medical Director, Auckland Cancer Trials Centre and Medical Oncologist


Address: Testing, testing….trials here and on the horizon

Dr Sanjeev Deva is a medical oncologist with a special interest in oncology phase I trials. He completed his training in Auckland in 2010, then went on to complete a Clinical Fellowship in Experimental Oncology at Guy’s and St. Thomas’ Hospital in London, United Kingdom. Since returning to Auckland in 2015, Dr Deva has established the Auckland Clinical Trials Centre at Auckland Hospital, where he is currently the Medical Director. He is the principal investigator on many ground-breaking studies and has collaborated with New Zealand’s leading researchers. Dr Deva is a sought-after lecturer, is an invited speaker at national conferences and is widely published in peer-reviewed journals.

Dr Chris JacksonMBChB FRACP

Medical Director, Cancer Society of New Zealand


Address: New Zealand’s quest for excellence in the delivery of melanoma care

Dr Chris Jackson is a medical oncologist who specialises in melanoma, gastro intestinal and urological cancers. He graduated from the University of Otago and trained in New Zealand before working at the Royal Marsden Hospital in London – the world’s first specialist cancer hospital. Dr Jackson currently works at Dunedin Hospital as a consultant medical oncologist for the Southern Blood and Cancer Service. He also works at the University of Otago as a Senior Lecturer and researcher in the Dunedin School of Medicine Centre for Translational Cancer Research. Dr Jackson was appointed as Medical Director of the Cancer Society of New Zealand in 2015. He has a leadership role in Cancer Trials New Zealand and co-founded Mercy Cancer Care, providing specialist oncology services to the lower South Island.

28

REGISTERED

FUNDED

ADVANCED MELANOMA2

SEP

2015

SEP

2016

CLASSICHODGKIN’SLYMPHOMA2

JULY

2017

FIRST LINE UROTHELIAL CARCINOMA2

SECOND LINE UROTHELIAL CARCINOMA2

OCT

2017OCT

2017

COMBINATION THERAPY FOR

ADVANCED NSCLC2

JUN

2017

FIRST LINE ADVANCED

NSCLC2

APR

2017

SECOND LINE ADVANCED

NSCLC2

AUG

2016

AUGUST 2018

NEW ZEALAND

UPDATE KEYTRUDA is now registered in seven indications1

Access to the latest information and practical resources to support your patients and manage their treatment.

We have a range of useful resources available either directly for you, or for you to provide to your patients.

To help describe the basics of immunotherapy to your patients and their families, an educational video is available via the KEYTRUDA patient website fightcancer.co.nz

Discover more about KEYTRUDA

Educational resources

An overview of immunotherapy video for patients

KEYTRUDA Healthcare Professional Website keytruda.co.nz

MSD8787_Keytruda - Satchel Insert MELNET_v1.indd 1 8/08/18 3:04 PM

29

KEYTRUDA Patient Websitefightcancer.co.nzInformation, resources and support for patients considering or already receiving KEYTRUDA treatment. This website also includes information around how to access KEYTRUDA in New Zealand.

Reference: 1. MSD Data on File. 2. KEYTRUDA Data Sheet

KEYTRUDA (pembrolizumab) 50mg powder for infusion. Before prescribing KEYTRUDA, read the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects available at www.medsafe.govt.nz or on request from Merck Sharp & Dohme (New Zealand) Limited. Prescription Only Medicine. Indication: As monotherapy for the treatment of unresectable or metastatic melanoma in adults. In combination with pemetrexed and platinum chemotherapy for first-line treatment of metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations. As monotherapy for first-line treatment of patients with metastatic NSCLC whose tumours express PD-L1 ≥50% tumour proportion score (TPS) on a validated test, with no EGFR or ALK genomic tumour aberrations. As monotherapy for the treatment of patients with advanced NSCLC with a PD-L1 TPS level ≥1% and who have received platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received prior therapy for these aberrations prior to receiving KEYTRUDA. As monotherapy for refractory/ relapsed classical Hodgkin Lymphoma (cHL). As monotherapy for patients with locally advanced/ metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, or who have received platinum-containing chemotherapy. See full data sheet. Contraindications: None. Precautions: Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, nephritis, hypophysitis, type 1 diabetes mellitus, hyperthyroidism, hypothyroidism, thyroiditis, uveitis, myositis, Guillain-Barre syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic syndrome, severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), and severe infusion reactions including hypersensitivity and anaphylaxis. Severe and fatal cases of immune-mediated adverse reactions have occurred. Increased mortality when in combination with dexamethasone and a thalidomide analogue in multiple myeloma (not indicated). Immune-mediated adverse reactions affecting more than one body system can occur simultaneously. For management of immune-mediated adverse events, see full data sheet. Limited information in patients with active infection and patients with on-going adverse reaction to ipilimumab – use caution. Acute graft-versus-host-disease (potentially fatal) in patients with history of allogeneic HSCT. Post-marketing: solid organ transplant rejection and myocarditis. See full data sheet for further information. Interactions: None expected. Avoid corticosteroids or immunosuppressants prior to treatment. Side effects: Clinical trials (treatment-related only): nasopharyngitis, anaemia, neutropenia, hypothyroidism, decreased appetite, dizziness, headache, cough, dyspnea, abdominal pain, constipation, diarrhea, nausea, vomiting, erythema, pruritus, rash, vitiligo, arthralgia, back pain, myalgia, pain in extremity, asthenia, chills, fatigue, oedema peripheral, pyrexia, colitis, hepatitis, hyperthyroidism, hypophysitis, nephritis, pneumonitis, type 1 diabetes mellitus, adrenal insufficiency, autoimmune hepatitis, alopecia, upper respiratory tract infection. Dosage and administration: The recommended dose of KEYTRUDA is 200 mg for previously untreated NSCLC, cHL, and urothelial carcinoma, and 2 mg/kg or 200 mg for melanoma or previously treated NSCLC (administered as an intravenous infusion over 30 minutes every 3 weeks). KEYTRUDA should be administered first when given in combination with pemetrexed and platinum chemotherapy. Treat with KEYTRUDA until disease progression or unacceptable toxicity. Atypical responses (i.e. an initial transient increase in tumour size or small new lesions followed by shrinkage) have been observed. Clinically stable patients (i.e. asymptomatic and not requiring urgent intervention) with initial evidence of progression can remain on treatment until confirmed. See full data sheet for further information, including details on PD-L1 testing. KEYTRUDA is a funded medicine for melanoma patients - restrictions apply. KEYTRUDA is a private purchase medicine for NSCLC, cHL and urothelial carcinoma patients. Based on data sheet prepared 08 June 2018. Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland. ONCO-1230760-0045 DA1835MW August 2018 essence MSD8787

MSD8787_Keytruda - Satchel Insert MELNET_v1.indd 2 8/08/18 3:04 PM

30

Mobile phonesPlease ensure your mobile is switched off or on silent mode during all conference sessions.

Name badgePlease wear your conference name badge for the duration of the Summit.

Conference wifiComplimentary wifi is available for conference delegates.

Name: Cordis

Password: melanoma

Continuing Medical EducationThe 2018 New Zealand Melanoma Summit has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 6 and 5.5 CME credits (per day) for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.

The 2018 New Zealand Melanoma Summit has been approved in the Royal Australasian College of Surgeons (RACS) CPD Program. Fellows participating in the two-day Summit can claim 13 Points in Maintenance of Knowledge and Skills. RACS members who wish to receive credit must provide their RACS member ID to the MelNet Coordinator ([email protected]) no later than 9 November 2018.

A certificate of attendance will be emailed to you after the Summit.

Responsible hostingThe MelNet Executive Committee and the Health Promotion Agency are responsible hosts. Therefore food, water and non-alcoholic drinks will be offered at the poster session and conference dinner.

DisclaimerThe programme was correct at the time of publication, however there may be minor changes during the event which will be well communicated to delegates.

AcknowledgementsThe MelNet Executive Committee and the Health Promotion Agency, as hosts of the 2018 New Zealand Melanoma Summit, would like to thank all of the speakers, especially the international guests, as well as the chairs, panellists and presenters of the breakout sessions. All have been very generous in donating their time and expertise. We would also like to thank our sponsorship partners whose support has made this event possible. The MelNet Executive Committee acknowledges and thanks the Health Promotion Agency and its staff, who freely gave their time and energy to plan the 2018 New Zealand Melanoma Summit. Without the ongoing support of the Health Promotion Agency, MelNet as an organisation and its ability to co-host these Summits would not be possible.

MelNet Executive Committee

Mr Gary Duncan, Plastic Surgeon, Co-Chair

Dr Chris Boberg, General Practitioner with special interest in skin cancer, Co-Chair

Dr Catherine Barrow, Consultant Medical Oncologist

Megan Chapman, Health Promotion Agency

Professor Mike Eccles, Biomedical Researcher

Trish Leathem, Skin Cancer Clinical Nurse Specialist

Mr Richard Martin, Cutaneous Surgical Oncologist

Mr Jeremy Simcock, Plastic Surgeon

Dr Ian Coutts, Dermatologist

Dr Richard Massey, Pathologist

Te ArohaWaiata for the 2018 New Zealand Melanoma Summit

Te arohaTe whakaponoMe te rangimarie Tātou, tātou e

Translation:

LoveFaithAnd PeaceBe Amongst Us All

General information

Programme - MelNet€¦ · 7 Programme Welcome Room: The Great Room 0830 Welcome 0845 Opening...

Documents

Transcript of Programme - MelNet€¦ · 7 Programme Welcome Room: The Great Room 0830 Welcome 0845 Opening...